<PubmedArticle>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">26766970</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>01</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1759-7706</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>5</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Thoracic cancer</Title>
<ISOAbbreviation>Thorac Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports.</ArticleTitle>
<Pagination>
<MedlinePgn>38-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/1759-7714.12049</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis (LM) treatment in recent years.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This paper reports two cases of advanced lung adenocarcinoma with exon-EGFR19 mutation. LM occurred during gefitinib treatment with an extracranial condition under control. Later, erlotinib was adopted with a recurrent response.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The progression free survival of both patients was over six months and their LM was under control for six and a half and nine months, respectively. LM may be sensitive on different levels to different EGFR-TKIs.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Erlotinib can be used to replace gefitinib if intracranial tumor progress occurs during gefitinib treatment. However, our conclusion still needs to be proven by further clinical research.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xing</LastName>
<ForeName>Puyuan</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Cancer Hospital Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Junling</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Cancer Hospital Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Yuankai</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Cancer Hospital Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Xiangru</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Cancer Hospital Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>01</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Singapore</Country>
<MedlineTA>Thorac Cancer</MedlineTA>
<NlmUniqueID>101531441</NlmUniqueID>
<ISSNLinking>1759-7706</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EGFR</Keyword>
<Keyword MajorTopicYN="N">LM</Keyword>
<Keyword MajorTopicYN="N">TKIs</Keyword>
<Keyword MajorTopicYN="N">erlotinib</Keyword>
<Keyword MajorTopicYN="N">lung adenocarcinoma</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>04</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2013</Year>
<Month>04</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26766970</ArticleId>
<ArticleId IdType="doi">10.1111/1759-7714.12049</ArticleId>
<ArticleId IdType="pmc">PMC4704275</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Tohoku J Exp Med. 2008 Apr;214(4):359-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18441512</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 2011 Oct;68(4):1089-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21681573</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2003 Nov 1;21(21):4060-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14581429</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2002 Nov 1;20(21):4292-302</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12409327</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurooncol. 2005 Oct;75(1):85-99</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16215819</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2001 Jul 1;19(13):3267-79</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11432895</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Treat Rev. 1999 Apr;25(2):103-19</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10395835</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Thorac Oncol. 2009 Nov;4(11):1415-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19692934</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 2011 Jun;67(6):1465-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21274533</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2009 Jul;65(1):80-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19059670</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2010 Dec 1;16(23):5873-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21030498</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2007 Sep;57(3):359-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17434236</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2009 Sep;65(3):351-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19157632</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Thorac Oncol. 2010 Jul;5(7):950-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20479691</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2006 Sep 20;24(27):4517-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16983123</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2007 Mar 1;13(5):1511-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17332296</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2002 Aug 1;95(3):605-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12209754</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>